Global Chronic Kidney Disease (CKD) Drugs Market: Industry Analysis and Forecast (2019-2026) – by Drug Class, End User, and Region.

Global Chronic Kidney Disease (CKD) Drugs Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period. To know about the Research Methodology :- Request Free Sample Report Chronic Kidney Disease (CKD) is also known as chronic kidney failure characterized by gradual loss of kidney function. There are different types of medications available in the market. Medicines cannot reverse chronic kidney disease (CKD), on the other hand, they are used to treat complications and to slow further kidney damage. With an increase in the occurrence of chronic kidney conditions, the global market for chronic kidney disease (CKD) drugs will witness good growth over the forecast period. The expected market growth is attributed to a steady rise in the prevalence of chronic kidney diseases, the prevalence of diabetes and metabolic conditions, and growth in the geriatric population. Important fulfilled requirements and beneficial return policies are also boosting the global chronic kidney disease (CKD) drug market. Certain factors such as fierce competition from Biosimilars and increasing inclinations of generic drugs might hamper the chronic kidney disease (CKD) drugs market growth to an extent. According to the end user segment, in 2018, hospitals accounted for the maximum share, followed by specialty clinics, thanks to the availability of technologically-advanced diagnostic equipment for the early diagnosis of the condition. Region-wise, North America is dominant in the global chronic kidney disease (CKD) drugs market, followed by the Asia Pacific and Europe. The US dominates the chronic kidney disease (CKD) drug market on account of the presence of a majority of chronic kidney disease (CKD) drug manufacturers in the region. Though, the fastest growth rate is expected to be in the Asia Pacific region because of the large kidney disease patient population and increasing consciousness about the disease. The objective of the report is to present a comprehensive analysis of the Global Chronic Kidney Disease (CKD) Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by Application. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by Application on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Chronic Kidney Disease (CKD) Drugs Market dynamics, structure by analyzing the market segments and project the Global Chronic Kidney Disease (CKD) Drugs Market size. Clear representation of competitive analysis of key players by Type, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Chronic Kidney Disease (CKD) Drugs Market make the report investor’s guide. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Scope of the Global Chronic Kidney Disease (CKD) Drugs Market: Inquire before buying

Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class

• ACE Inhibitors • Angiotensin-II receptor blockers • Calcium channel blockers • Beta blockers • Erythropoiesis-stimulating agents (ESAs) • Diuretics • Others

Global Chronic Kidney Disease (CKD) Drugs Market, By End User

• Hospitals • Specialty Clinics

Global Chronic Kidney Disease (CKD) Drugs Market, By Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Key players operating in Global Chronic Kidney Disease (CKD) Drugs Market

• Keryx Biopharmaceuticals, Inc. • Kissei Pharmaceutical Co., Ltd. • AbbVie, Inc. • GlaxoSmithKline plc. • Sanofi S.A. • F. Hoffmann-La Roche Ltd. • Pfizer, Inc. • AstraZeneca plc • Amgen Inc. • Teva Pharmaceutical Industries Ltd. • Allergan plc. • FibroGen • Johnson & Johnson • Ardelyx, Inc. • Reata Pharmaceuticals, Inc.  
Global Chronic Kidney Disease (CKD) Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Chronic Kidney Disease (CKD) Drugs Market, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast 6.1. Global Chronic Kidney Disease (CKD) Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by End User 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End User 7.4. Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Bn) Forecast, by End User 7.5. Global Chronic Kidney Disease (CKD) Drugs Market Analysis, by End User 7.6. Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End User 8. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by Drug Class 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class 8.4. Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Bn) Forecast, by Drug Class 8.5. Global Chronic Kidney Disease (CKD) Drugs Market Analysis, by Drug Class 8.6. Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class 9. Global Chronic Kidney Disease (CKD) Drugs Market Analysis, by Region 9.1. Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Region 9.2. Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Bn) Forecast, by Region 9.3. Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Region 10. North America Chronic Kidney Disease (CKD) Drugs Market Analysis 10.1. Key Findings 10.2. North America Chronic Kidney Disease (CKD) Drugs Market Overview 10.3. North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End User 10.4. North America Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 10.4.1. Hospitals 10.4.2. Specialty Clinics 10.5. North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class 10.6. North America Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 10.6.1. ACE Inhibitors 10.6.2. Angiotensin-II receptor blockers 10.6.3. Calcium channel blockers 10.6.4. Beta blockers 10.6.5. Erythropoiesis-stimulating agents (ESAs) 10.6.6. Diuretics 10.6.7. Others 10.7. North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country 10.8. North America Chronic Kidney Disease (CKD) Drugs Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Chronic Kidney Disease (CKD) Drugs Market Analysis, by Country 10.10. U.S. Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 10.10.1. Hospitals 10.10.2. Specialty Clinics 10.11. U.S. Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 10.11.1. ACE Inhibitors 10.11.2. Angiotensin-II receptor blockers 10.11.3. Calcium channel blockers 10.11.4. Beta blockers 10.11.5. Erythropoiesis-stimulating agents (ESAs) 10.11.6. Diuretics 10.11.7. Others 10.12. Canada Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 10.12.1. Hospitals 10.12.2. Specialty Clinics 10.13. Canada Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 10.13.1. ACE Inhibitors 10.13.2. Angiotensin-II receptor blockers 10.13.3. Calcium channel blockers 10.13.4. Beta blockers 10.13.5. Erythropoiesis-stimulating agents (ESAs) 10.13.6. Diuretics 10.13.7. Others 10.14. North America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis 10.14.1. By End User 10.14.2. By Drug Class 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Chronic Kidney Disease (CKD) Drugs Market Analysis 11.1. Key Findings 11.2. Europe Chronic Kidney Disease (CKD) Drugs Market Overview 11.3. Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End User 11.4. Europe Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 11.4.1. Hospitals 11.4.2. Specialty Clinics 11.5. Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class 11.6. Europe Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 11.6.1. ACE Inhibitors 11.6.2. Angiotensin-II receptor blockers 11.6.3. Calcium channel blockers 11.6.4. Beta blockers 11.6.5. Erythropoiesis-stimulating agents (ESAs) 11.6.6. Diuretics 11.6.7. Others 11.7. Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country 11.8. Europe Chronic Kidney Disease (CKD) Drugs Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Chronic Kidney Disease (CKD) Drugs Market Analysis, by Country 11.10. Germany Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 11.10.1. Hospitals 11.10.2. Specialty Clinics 11.11. Germany Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 11.11.1. ACE Inhibitors 11.11.2. Angiotensin-II receptor blockers 11.11.3. Calcium channel blockers 11.11.4. Beta blockers 11.11.5. Erythropoiesis-stimulating agents (ESAs) 11.11.6. Diuretics 11.11.7. Others 11.12. U.K. Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 11.12.1. Hospitals 11.12.2. Specialty Clinics 11.13. U.K. Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 11.13.1. ACE Inhibitors 11.13.2. Angiotensin-II receptor blockers 11.13.3. Calcium channel blockers 11.13.4. Beta blockers 11.13.5. Erythropoiesis-stimulating agents (ESAs) 11.13.6. Diuretics 11.13.7. Others 11.14. France Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 11.14.1. Hospitals 11.14.2. Specialty Clinics 11.15. France Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 11.15.1. ACE Inhibitors 11.15.2. Angiotensin-II receptor blockers 11.15.3. Calcium channel blockers 11.15.4. Beta blockers 11.15.5. Erythropoiesis-stimulating agents (ESAs) 11.15.6. Diuretics 11.15.7. Others 11.16. Italy Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 11.16.1. Hospitals 11.16.2. Specialty Clinics 11.17. Italy Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 11.17.1. ACE Inhibitors 11.17.2. Angiotensin-II receptor blockers 11.17.3. Calcium channel blockers 11.17.4. Beta blockers 11.17.5. Erythropoiesis-stimulating agents (ESAs) 11.17.6. Diuretics 11.17.7. Others 11.18. Spain Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 11.18.1. Hospitals 11.18.2. Specialty Clinics 11.19. Spain Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 11.19.1. ACE Inhibitors 11.19.2. Angiotensin-II receptor blockers 11.19.3. Calcium channel blockers 11.19.4. Beta blockers 11.19.5. Erythropoiesis-stimulating agents (ESAs) 11.19.6. Diuretics 11.19.7. Others 11.20. Rest of Europe Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 11.20.1. Hospitals 11.20.2. Specialty Clinics 11.21. Rest of Europe Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 11.21.1. ACE Inhibitors 11.21.2. Angiotensin-II receptor blockers 11.21.3. Calcium channel blockers 11.21.4. Beta blockers 11.21.5. Erythropoiesis-stimulating agents (ESAs) 11.21.6. Diuretics 11.21.7. Others 11.22. Europe Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis 11.22.1. By End User 11.22.2. By Drug Class 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Development 12. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis 12.1. Key Findings 12.2. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Overview 12.3. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End User 12.4. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 12.4.1. Hospitals 12.4.2. Specialty Clinics 12.5. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class 12.6. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 12.6.1. ACE Inhibitors 12.6.2. Angiotensin-II receptor blockers 12.6.3. Calcium channel blockers 12.6.4. Beta blockers 12.6.5. Erythropoiesis-stimulating agents (ESAs) 12.6.6. Diuretics 12.6.7. Others 12.7. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country 12.8. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis, by Country 12.10. China Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 12.10.1. Hospitals 12.10.2. Specialty Clinics 12.11. China Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 12.11.1. ACE Inhibitors 12.11.2. Angiotensin-II receptor blockers 12.11.3. Calcium channel blockers 12.11.4. Beta blockers 12.11.5. Erythropoiesis-stimulating agents (ESAs) 12.11.6. Diuretics 12.11.7. Others 12.12. India Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 12.12.1. Hospitals 12.12.2. Specialty Clinics 12.13. India Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 12.13.1. ACE Inhibitors 12.13.2. Angiotensin-II receptor blockers 12.13.3. Calcium channel blockers 12.13.4. Beta blockers 12.13.5. Erythropoiesis-stimulating agents (ESAs) 12.13.6. Diuretics 12.13.7. Others 12.14. Japan Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 12.14.1. Hospitals 12.14.2. Specialty Clinics 12.15. Japan Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 12.15.1. ACE Inhibitors 12.15.2. Angiotensin-II receptor blockers 12.15.3. Calcium channel blockers 12.15.4. Beta blockers 12.15.5. Erythropoiesis-stimulating agents (ESAs) 12.15.6. Diuretics 12.15.7. Others 12.16. ASEAN Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 12.16.1. Hospitals 12.16.2. Specialty Clinics 12.17. ASEAN Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 12.17.1. ACE Inhibitors 12.17.2. Angiotensin-II receptor blockers 12.17.3. Calcium channel blockers 12.17.4. Beta blockers 12.17.5. Erythropoiesis-stimulating agents (ESAs) 12.17.6. Diuretics 12.17.7. Others 12.18. Rest of Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 12.18.1. Hospitals 12.18.2. Specialty Clinics 12.19. Rest of Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 12.19.1. ACE Inhibitors 12.19.2. Angiotensin-II receptor blockers 12.19.3. Calcium channel blockers 12.19.4. Beta blockers 12.19.5. Erythropoiesis-stimulating agents (ESAs) 12.19.6. Diuretics 12.19.7. Others 12.20. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis 12.20.1. By End User 12.20.2. By Drug Class 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Development 13. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Overview 13.3. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End User 13.4. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 13.4.1. Hospitals 13.4.2. Specialty Clinics 13.5. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class 13.6. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 13.6.1. ACE Inhibitors 13.6.2. Angiotensin-II receptor blockers 13.6.3. Calcium channel blockers 13.6.4. Beta blockers 13.6.5. Erythropoiesis-stimulating agents (ESAs) 13.6.6. Diuretics 13.6.7. Others 13.7. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country 13.8. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Analysis, by Country 13.10. GCC Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 13.10.1. Hospitals 13.10.2. Specialty Clinics 13.11. GCC Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 13.11.1. ACE Inhibitors 13.11.2. Angiotensin-II receptor blockers 13.11.3. Calcium channel blockers 13.11.4. Beta blockers 13.11.5. Erythropoiesis-stimulating agents (ESAs) 13.11.6. Diuretics 13.11.7. Others 13.12. South Africa Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 13.12.1. Hospitals 13.12.2. Specialty Clinics 13.13. South Africa Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 13.13.1. ACE Inhibitors 13.13.2. Angiotensin-II receptor blockers 13.13.3. Calcium channel blockers 13.13.4. Beta blockers 13.13.5. Erythropoiesis-stimulating agents (ESAs) 13.13.6. Diuretics 13.13.7. Others 13.14. Rest of Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 13.14.1. Hospitals 13.14.2. Specialty Clinics 13.15. Rest of Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 13.15.1. ACE Inhibitors 13.15.2. Angiotensin-II receptor blockers 13.15.3. Calcium channel blockers 13.15.4. Beta blockers 13.15.5. Erythropoiesis-stimulating agents (ESAs) 13.15.6. Diuretics 13.15.7. Others 13.16. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis 13.16.1. By End User 13.16.2. By Drug Class 13.17. PEST Analysis 13.18. Key Trends 13.19. Key Development 14. South America Chronic Kidney Disease (CKD) Drugs Market Analysis 14.1. Key Findings 14.2. South America Chronic Kidney Disease (CKD) Drugs Market Overview 14.3. South America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End User 14.4. South America Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 14.4.1. Hospitals 14.4.2. Specialty Clinics 14.5. South America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class 14.6. South America Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 14.6.1. ACE Inhibitors 14.6.2. Angiotensin-II receptor blockers 14.6.3. Calcium channel blockers 14.6.4. Beta blockers 14.6.5. Erythropoiesis-stimulating agents (ESAs) 14.6.6. Diuretics 14.6.7. Others 14.7. South America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country 14.8. South America Chronic Kidney Disease (CKD) Drugs Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Chronic Kidney Disease (CKD) Drugs Market Analysis, by Country 14.10. Brazil Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 14.10.1. Hospitals 14.10.2. Specialty Clinics 14.11. Brazil Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 14.11.1. ACE Inhibitors 14.11.2. Angiotensin-II receptor blockers 14.11.3. Calcium channel blockers 14.11.4. Beta blockers 14.11.5. Erythropoiesis-stimulating agents (ESAs) 14.11.6. Diuretics 14.11.7. Others 14.12. Mexico Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 14.12.1. Hospitals 14.12.2. Specialty Clinics 14.13. Mexico Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 14.13.1. ACE Inhibitors 14.13.2. Angiotensin-II receptor blockers 14.13.3. Calcium channel blockers 14.13.4. Beta blockers 14.13.5. Erythropoiesis-stimulating agents (ESAs) 14.13.6. Diuretics 14.13.7. Others 14.14. Rest of South America Chronic Kidney Disease (CKD) Drugs Market Forecast, by End User 14.14.1. Hospitals 14.14.2. Specialty Clinics 14.15. Rest of South America Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 14.15.1. ACE Inhibitors 14.15.2. Angiotensin-II receptor blockers 14.15.3. Calcium channel blockers 14.15.4. Beta blockers 14.15.5. Erythropoiesis-stimulating agents (ESAs) 14.15.6. Diuretics 14.15.7. Others 14.16. South America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis 14.16.1. By End User 14.16.2. By Drug Class 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Keryx Biopharmaceuticals, Inc. 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Kissei Pharmaceutical Co., Ltd. 15.3.3. AbbVie, Inc. 15.3.4. GlaxoSmithKline plc. 15.3.5. Sanofi S.A. 15.3.6. F. Hoffmann-La Roche Ltd. 15.3.7. Pfizer, Inc. 15.3.8. AstraZeneca plc 15.3.9. Amgen Inc. 15.3.10. Teva Pharmaceutical Industries Ltd. 15.3.11. Allergan plc. 15.3.12. FibroGen 15.3.13. Johnson & Johnson 15.3.14. Ardelyx, Inc. 15.3.15. Reata Pharmaceuticals, Inc. 16. Primary Key Insights

About This Report

Report ID39171
Category Medical Devices
Published DateDec 2019
Updated DateNov 2020
Contact Us